I spent years in the biotech industry, and I'm telling you right now: BioNTech's combination of bispecific antibodies and mRNA cancer shots is the closest thing to a holy grail that we've seen in a decade. At least, that's what I and most other researchers took away from the Annual Meeting of the American Association for Cancer Research (AACR) last weekend.
Most of you only know BioNTech because they developed the Pfizer COVID vaccine in 2021, allowing you to return to your lives of losing money behind the Wendy's dumpster. But the real gem are the founders, Ugur Sahin and Özlem Türeci. They're absolute geniuses. They aren't in it for the money; they just want to cure cancer. Google them. Their biographies would make even an Asian mother say, "I'm proud of you."
And they just announced that they will step down by the end of 2026 to start a new, research-driven spin-off. Why? Because their company, BioNTech, has finally grown up. They’re handing the keys to the ruthless US pharma suits to milk the commercialization phase while they go back to the lab to do what they do best.
Now, let's discuss the AACR NBC piece that every oncologist is talking about. Just search for "pancreatic cancer" on X (I can't share links here):
They highlighted BNT116, their off-the-shelf mRNA shot for Non-Small Cell Lung Cancer (NSCLC). Historically, this diagnosis was a death sentence. Now half of the people who got this little vaccine are cancer-free, even 6 years after they got the shot. And all of this in a Stage 1 study, with a vaccine which is less than refined yet. Yes, BNT116 is early stage, but the immune responses we're seeing are off the charts. Add to that BNT122 (autogene cevumeran) in Phase 2 for colorectal cancer (custom-built mRNA for individual patient tumors) and the upside potential here is through the roof.
But BNTX offers more than just mRNA cancer vaccines. Its oncology pipeline is huge. In total, BioNTech has 29 indications in Phase 2 and Phase 3 studies. While I don't expect all of them to succeed, if you go by normal oncology approval statistics, at least a few will. The crown jewel is BNT327 (pumitamig), a PD-L1/VEGF bispecific antibody. It's so potent that last year, Bristol Myers Squibb (BMS) signed a deal worth up to $11.1 billion, splitting global profits 50/50. BNTX has above $20 billion in cash reserves that have remained stable for years due to interest and milestone payments. This provides the ultimate downside protection. They also have their (shrinking) Covid business, which generates over 1 billion USD in cash flow each year.
Do the math: The cash plus the 50% BNT327 BMS deal exceeds BNTX's market cap by a large margin. You're essentially getting the rest of the pipeline and the profitable Covid business for free. BNT327 has been filed for an uncountable number of cancer types and is gearing up to compete with Keytruda, a $25 billion-a-year drug.
**Upcoming catalysts to print your tendies:**
\* Early May: Pivotal data for Gotistobart (BNT316, their anti-CTLA-4 antibody). If the Objective Response Rate (ORR) beats the standard of care in advanced solid tumors, the stock rockets.
\* Late May: Global Phase 3 readout (DYNASTY-Breast02) for BNT323 (DB-1303, their HER2 ADC) in breast cancer.
\* Late May / Early June (ASCO): The Super Bowl of oncology. Expect a massive info dump here. We need fresh combo data from the BNT327 trials. If the safety profile holds up without crazy toxicities, it's a wrap.
\* H2 2026: FDA filing for BNT323 in endometrial cancer, riding on ridiculous Phase 2 data showing an ORR of roughly 58%.
\* H2 2026: Results for BNT113 (HPV16+ head/neck cancer) and the Phase 2/3 AHEAD-MERIT trial. Hard mRNA data that will finally re-rate the entire company.
**My Position:**
$120,000 in BNTX 2028 $115 Leaps. 💎🙌
I think the upside over the course of 2026 is massive as they switch to commercial mode.